Alternate molecular genetic pathways in ovarian carcinomas of common histological types.

[1]  Rochelle L. Garcia,et al.  Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. , 2005, American journal of obstetrics and gynecology.

[2]  D. Bell,et al.  Origins and molecular pathology of ovarian cancer , 2005, Modern Pathology.

[3]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[4]  J. Prat,et al.  Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. , 2004, Human pathology.

[5]  Chung-Liang Ho,et al.  Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors , 2004, Cancer Research.

[6]  C. Gilks,et al.  Subclassification of Ovarian Surface Epithelial Tumors Based on Correlation of Histologic and Molecular Pathologic Data , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[7]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[8]  B. Modan,et al.  Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. , 2004, American journal of obstetrics and gynecology.

[9]  A. Flanagan,et al.  In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours , 2004, The Journal of pathology.

[10]  J. Barnholtz-Sloan,et al.  Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. , 2003, American journal of obstetrics and gynecology.

[11]  J. Cigudosa,et al.  Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. , 2003, Cancer research.

[12]  Oscar Lin,et al.  Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. , 2003, Gynecologic oncology.

[13]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[14]  Hong Wu,et al.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. , 2003, Cancer cell.

[15]  A. Magliocco,et al.  A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors , 2003, Cancer.

[16]  Satoshi Matsumoto,et al.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas , 2002, Nature Genetics.

[17]  L. Mayo,et al.  The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. , 2002, Trends in biochemical sciences.

[18]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[19]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[20]  Mef Nilbert,et al.  Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis , 2002, Cancer.

[21]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[22]  M. Saegusa,et al.  Frequent nuclear β‐catenin accumulation and associated mutations in endometrioid‐type endometrial and ovarian carcinomas with squamous differentiation , 2001, The Journal of pathology.

[23]  M. Noguchi,et al.  Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. , 2000, Cancer research.

[24]  T. Yoshimoto,et al.  Functional evaluation of p53 and PTEN gene mutations in gliomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  Mitsuaki Suzuki,et al.  Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.

[26]  J. Herman,et al.  hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. , 1999, The American journal of pathology.

[27]  G. Chenevix-Trench,et al.  β‐Catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours , 1999, International journal of cancer.

[28]  G. Chenevix-Trench,et al.  Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. , 1998, Cancer research.

[29]  J. Palacios,et al.  Mutations in the β-Catenin Gene (CTNNB1) in Endometrioid Ovarian Carcinomas , 1998 .

[30]  A. Okamoto,et al.  Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. , 1991, Cancer research.

[31]  T. Jacks,et al.  Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer , 2005, Nature Medicine.

[32]  P. Humphrey,et al.  Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. , 1993, Obstetrics and gynecology.

[33]  T. Ulbright,et al.  Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. , 1985, Human pathology.